InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Metagenomi Therapeutics, Inc.

MGX Clue Score24
United States Fiscal year ends December CIK 0001785279
$1.00 +0.68% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.00 −68.05% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 9 Feb 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2023Revenue44.8Operating income−78.5Net income−68.3EPS, diluted−20.05Fiscal year 2024Revenue52.3 +16.8%Operating income−88.9Net income−78.1EPS, diluted−2.36Fiscal year 2025Revenue25.2 −51.8%Operating income−96.0Net income−87.9EPS, diluted−2.36
FY2023FY2024FY2025
Revenue 44.8 52.3 25.2
Growth +16.8% −51.8%
Operating income −78.5 −88.9 −96.0
Net income −68.3 −78.1 −87.9
Growth
EPS, diluted −20.05 −2.36 −2.36

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2023Operating margin−175.4%Net margin−152.5%Free cash flow margin−226.2%Fiscal year 2024Operating margin−170.0%Net margin−149.3%Free cash flow margin−214.5%Fiscal year 2025Operating margin−380.9%Net margin−348.5%Free cash flow margin−354.9%
FY2023FY2024FY2025
Operating margin −175.4% −170.0% −380.9%
Net margin −152.5% −149.3% −348.5%
Free cash flow margin −226.2% −214.5% −354.9%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−91.4Capital expenditure−9.8Free cash flow−101.2Fiscal year 2024Operating cash flow−109.1Capital expenditure−3.1Free cash flow−112.2Fiscal year 2025Operating cash flow−88.9Capital expenditure−0.6Free cash flow−89.5
FY2023FY2024FY2025
Operating cash flow −91.4 −109.1 −88.9
Capital expenditure −9.8 −3.1 −0.6
Free cash flow −101.2 −112.2 −89.5
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash140.6Shareholders’ equity−135.6Fiscal year 2024Cash27.4Shareholders’ equity234.9Fiscal year 2025Cash41.7Shareholders’ equity158.6
FY2023FY2024FY2025
Cash 140.6 27.4 41.7
Shareholders’ equity −135.6 234.9 158.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−175.4% −170.0% −380.9%
−134.6% −159.8% −348.8%
−152.5% −149.3% −348.5%
−226.2% −214.5% −354.9%
Spending
210.9% 208.8% 374.6%
64.4% 61.2% 106.3%
21.9% 6.0% 2.3%
Returns
n/a −33.2% −55.4%
−18.7% −24.0% −39.7%
Balance and payout
41.0% 27.6% 28.3%